Load Loss Performance of an Autonomous Self-Excited Induction Generator

This paper presents a dynamic analysis of an autonomous Self-Excited Induction Generator (SEIG) showing dynamic loss of load performance. In stand-alone operation of the SEIG, especially when supplying a low power utility, an interesting performance of the SEIG observed for various power factor loads can be harnessed to maximise the use of the SEIG. Analysis is carried out based of the d-q axis model, while considering the performance characteristics of the machine at constant machine speed, capacitor value and for various power factor loads. The transient surge, its decay and rise on the various machine variables – phase voltage, phase current, capacitor current and load current are investigated for a gain and subsequent loss of load. The time it takes to excite the machine is also considered for the various power factors on an unloaded condition. The effects of the loading on the frequency, as well as the drop in the value of the monitored parameters are also investigated

Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis

Primary Liver Cancer (PLC) is the leading cause of death by cancer among males in Thailand and the 3rd among females. Most cases are hepatocellular carcinoma (HCC) but cholangiocarcinomas represent between 4 and 80% of liver cancers depending upon geographic area. Most HCC are associated with chronic infection by Hepatitis B Virus while a G→T mutation at codon 249 of the TP53 gene, R249S, specific for exposure to aflatoxin, is detected in tumors for up to 30% of cases. We have used Short Oligonucleotide Mass Analysis (SOMA) to quantify free circulating R249S-mutated DNA in plasma using blood specimens collected in a hospital case:control study. Plasma R249S-mutated DNA was detectable at low concentrations (≥67 copies/mL) in 53 to 64% of patients with primary liver cancer or chronic liver disease and in 19% of controls. 44% of patients with HCC and no evidence of cirrhosis had plasma concentrations of R249S-mutated DNA ≥150 copies/mL, compared to 21% in patients with both HCC and cirrhosis, 22% in patients with cholangiocarcinoma, 12% in patients with non-cancer chronic liver disease and 3% of subjects in the reference group. Thus, plasma concentrations of R249S-mutated DNA ≥150 copies/mL tended to be more common in patients with HCC developing without pre-existing cirrhosis (p = 0.027). Overall, these results support the preferential occurrence of R249S-mutated DNA in HCC developing in the absence of cirrhosis in a context of HBV chronic infection